Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial

The Lancet Infectious Diseases

Volumn 18, Issue 3, 2018, Pages 285-295

  Torres, Antoni ^a,b,c   Zhong, Nanshan ^d   Pachl, Jan ^e   Timsit, Jean François ^f   Kollef, Marin ^g   Chen, Zhangjing ^h   Song, Jie ^h   Taylor, Dianna ⁱ   Laud, Peter J ^j   Stone, Gregory G ^k   Chow, Joseph W ^k  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

^e CHARLES UNIVERSITY   (Czech Republic)

^f BICHAT HOSPITAL   (France)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h ASTRAZENECA   (United Kingdom)

ⁱ Taylormade Health   (United Kingdom)

^j UNIVERSITY OF SHEFFIELD   (United Kingdom)

^k PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AVIBACTAM; CEFTAZIDIME; MEROPENEM; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATRIAL FIBRILLATION; CONSTIPATION; CONTROLLED STUDY; DECUBITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; HEART FAILURE; HOSPITAL INFECTION; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INSOMNIA; KIDNEY FUNCTION; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON-INFERIORITY TRIAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY FAILURE; SIDE EFFECT; TACHYCARDIA; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING; CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; CEFTAZIDIME; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MEROPENEM; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 85039424423     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30747-8     Document Type: Article

References (30)

1. Magill, SS, Edwards, JR, Bamberg, W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370 (2014), 1198–1208.
2. Kollef, MH, Hamilton, CW, Ernst, FR, Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol 33 (2012), 250–256.
3. Kalil, AC, Metersky, ML, Klompas, M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63 (2016), e61–e111.
4. Jones, RN, Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 51:suppl 1 (2010), S81–S87.
5. MacVane, SH, Antimicrobial resistance in the intensive care unit: a focus on Gram-negative bacterial infections. J Intensive Care Med 32 (2016), 25–37.
6. Kaye, KS, Pogue, JM, Infections caused by resistant gram-negative bacteria: epidemiology and management. Pharmacotherapy 35 (2015), 949–962.
7. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf, 2013 (accessed March 23, 2017).
8. Luna, CM, Aruj, P, Niederman, MS, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 27 (2006), 158–164.
9. Zilberberg, MD, Nathanson, BH, Sulham, K, Fan, W, Shorr, AF, Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis, 17, 2017, 279.
10. Lagace-Wiens, P, Walkty, A, Karlowsky, JA, Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid 9 (2014), 13–25.
11. Lahiri, SD, Mangani, S, Durand-Reville, T, et al. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC beta-lactamases. Antimicrob Agents Chemother 57 (2013), 2496–2505.
12. Falcone, M, Paterson, D, Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother 71 (2016), 2713–2722.
13. De Jonge, BL, Karlowsky, JA, Kazmierczak, KM, Biedenbach, DJ, Sahm, DF, Nichols, WW, In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM Global Surveillance Study (2012 to 2014). Antimicrob Agents Chemother 60 (2016), 3163–3169.
14. Hackel, M, Kazmierczak, KM, Hoban, DJ, et al. Assessment of the in vitro activity of ceftazidime-avibactam against multidrug-resistant Klebsiella spp collected in the INFORM Global Surveillance Study, 2012 to 2014. Antimicrob Agents Chemother 60 (2016), 4677–4683.
15. Karlowsky, JA, Biedenbach, DJ, Kazmierczak, KM, Stone, GG, Sahm, DF, Activity of ceftazidime-avibactam against extended-spectrum- and AmpC beta-lactamase-producing enterobacteriaceae collected in the INFORM Global Surveillance Study from 2012 to 2014. Antimicrob Agents Chemother 60 (2016), 2849–2857.
16. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-second informational supplement. 2012, Clinical Laboratory Standards Institute, Wayne, PA.
17. European Medicines Agency. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500153953.pdf (accessed June 23, 2017).
18. Newcombe, RG, Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 17 (1998), 873–890.
19. Miettinen, O, Nurminen, M, Comparative analysis of two rates. Stat Med 4 (1985), 213–226.
20. Mazuski, JE, Gasink, L, Armstong, J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomised, controlled, double-blind, phase 3 program. Clin Infect Dis 62 (2016), 1380–1389.
21. Wagenlehner, FM, Sobel, JD, Newell, P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 63 (2016), 754–762.
22. Carmeli, Y, Armstrong, J, Laud, PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16 (2016), 661–673.
23. Lucasti, C, Popescu, I, Ramesh, MK, Lipka, J, Sable, C, Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother 68 (2013), 1183–1192.
24. Vazquez, JA, Gonzalez Patzan, LD, Stricklin, D, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 28 (2012), 1921–1931.
25. Pertel, PE, Bernardo, P, Fogarty, C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 46 (2008), 1142–1151.
26. File, TM Jr, Low, DE, Eckburg, PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 51 (2010), 1395–1405.
27. Li J, Zhou D, Das S, et al. PK/PD target attainment analyses and assessment of dose adjustments for renal insufficiency for ceftazidime-avibactam (CAZ-AVI) in patients with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) or nosocomial pneumonia (NP). American Association of Pharmaceutical Scientists Annual Meeting and Exposition; Orlando, FL, USA; Oct 25, 2015; abstr 2459.
28. AstraZeneca. Summary of product characteristics: Zavicefta. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004027/WC500210234.pdf (accessed May 18, 2017).
29. Allergan. AVYCAZ (ceftazidime-avibactam) for injection, for intravenous use: prescribing information. http://pi.actavis.com/data_stream.asp?product_group=1957&p=pi&language=E (accessed May 18, 2017).
30. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005), 388–416.